About Us


Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company developing potentially transformative therapies for patients affected by a range of metabolic diseases. We are focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases, and we are pioneering the study of MetAP2 therapeutics in both common and rare metabolic disorders.

What Drives Us


We are leveraging our proprietary understanding of the MetAP2 pathway to design a new generation of therapeutics that maximize efficacy and safety for patients.


We are advancing novel treatments for conditions where MetAP2 targeting has great potential – from type 2 diabetes to Prader-Willi syndrome and other rare or orphan diseases.


We are inspired by the unique needs of patients affected by a range of complex metabolic diseases – and the potential to deliver first-in-class therapies.